Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Does MannKind Finally Have What It Takes To Get Afrezza Inhaled Insulin Cleared By FDA?

This article was originally published in The Pink Sheet Daily

Executive Summary

Among other things, new FDA review will test whether the company has proven that data with an old device can be applied to the new inhaler the company plans to market. MannKind is not expecting an advisory committee meeting.

Advertisement

Related Content

MannKind’s Long, Winding Development Road Ends In Approval Of Afrezza Inhaled Insulin
Shutdown Week Two: Could Sponsors Find A More Focused FDA?
MannKind Gears Up To Make Commercial Case For Inhaled Insulin Afrezza
Nektar Seeking New Partner For Exubera As Pfizer Returns Rights

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074890

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel